APAC ADHD Therapeutics Market Report

APAC ADHD Therapeutics Market Size

The APAC ADHD Therapeutics Market is projected to grow from USD 3.16 billion in 2025 to USD 3.54 billion in 2026 and reach USD 8.96 billion by 2034, registering a CAGR of 12.30% from 2026 to 2034.

MARKET DRIVERS

The growing prevalence of attention deficit hyperactivity disorder among children, which is due to preterm, low birth weight of infants and increase in the constant environmental changes, unhealthy lifestyle, genetic factors, is majorly driving the growth of the ADHD therapeutics market in the APAC region. However, the occurrence of ADHD is primarily seen in the 4-8 or less than 12 years of age group.The growing population is significantly contributing to the APAC ADHD therapeutics market growth.

On the other hand, the increase in mental disorders among children, the rising investments from government and non-government organizations for developing various treatments and therapies for treating the conditions related to mental illness are expected to propel the market growth.

In addition, the increase in the initiatives for developing medical and health care awareness and infrastructure in the region is propelling the growth of the ADHD therapeutics market. Furthermore, the rising awareness about mental illness and disorders among the people also for providing better treatment and therapies for the conditions is expected to influence market growth positively. Also, the increase in screening tests and diagnostic procedures is expected to drive market growth. Furthermore, the growing competition between the players for developing new and effective products and medications by applying various strategies such as mergers and acquisitions is uplifting the growth in the ADHD therapeutics market in the APAC region.

However, the increase in the high costs of the treatment and procedures with the lack of proper reimbursement policies affects the market's growth. In addition, the issues related to the medication of the ADHD therapeutics, such as side effects, infection like allergies, anorexia, headaches, and other effects, are limiting the market's growth. On the other hand, the strict government rules and regulations for introducing a new product in the market with stringent approval procedures for approving new entry products are the other factors limiting the growth of the ADHD therapeutics market in the APAC region.

REPORT COVERAGE

SEGMENTAL ANALYSIS

REGIONAL ANALYSIS

The Asia Pacific market is projected to account for the highest share of the global ADHD therapeutics market during the forecast period. The market is expected to grow owing to the number of patients with ADHD, the increase in investments from government and non-government firms. According to a study on the rise in the prevalence of ADHD in primary school children is accounted as 11.32 percent in India; further, the study has shown that the probability of ADHD in males is higher than females that is 66.7 percent in males 16.33 percent in females. Also, the prevalence of ADHD in Australia among children is propelling the growth of the market. The major growth contributors in the region are China, India, and Japan.

However, China dominated the APAC ADHD therapeutics market in 2024. The factors such as an increase in the early adoption of new and advanced technology with the increasing initiatives for raising awareness among the people for growing medical and healthcare expenditure is driving the market growth of the ADHD therapeutics in the country.

KEY MARKET PLAYERS

A few of the promising companies in the APAC attention deficit hyperactivity disorder (ADHD) therapeutics market profiled in this report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).

MARKET SEGMENTATION

This research report on the APAC ADHD Therapeutics Market has been segmented and sub-segmented into the following categories.

Treatment by Medication

• Stimulants
  • Amphetamines
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
• Non-Stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • Others

Treatment by Psychotherapy

• Behavior Therapy
• Cognitive Behavioral Therapy
• Interpersonal Psychotherapy
• Family Therapy

Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy

Treatment by Education or Training

• Parent Management Training
• Social Skills Training
• School-Based Interventions

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC